Close menu




XPHYTO THERAPEUTICS

Photo credits: pixabay.com

Commented by André Will-Laudien on May 18th, 2022 | 12:48 CEST

Biotech stocks: BioNTech, XPhyto Therapeutics, Novavax, Valneva - Crashing, the choice remains difficult!

  • Biotechnology
  • Covid19

For pure play vaccine companies, the environment is getting tougher. On the one hand, the winter is over, and on the other, Corona has lost its horrors, especially as the Omicron variant presented like a cold for most infected people. 77.6% of the German population have received at least one vaccination dose so far. 63.1 million people have thus already received basic immunization, and 49.5 million people went for another shot. Only 4.6 million people, or 5.5%, have already received a second booster vaccination. 18.6 million people have not been vaccinated, or 22.4% of the population. With currently only 4,000 vaccinations per day, the many millions of vaccine doses ordered are likely to remain on the shelf. For vaccine manufacturers, future orders will plummet. Which Company has a plan B in place?

Read

Commented by Nico Popp on May 5th, 2022 | 11:52 CEST

Biotech-Investments also work conservatively: BioNTech, XPhyto, Valneva

  • Biotechnology
  • Pharma
  • Covid19

Biotech stocks are often seen as all-or-nothing investments - either a bet works out, or the companies disappear into oblivion. But innovative companies in the pharmaceutical and biotech sectors do not always operate in just one area. They are not always spectacular projects that are dependent on approval procedures. We outline the investment opportunities around three well-known biotech stocks.

Read

Commented by Armin Schulz on March 2nd, 2022 | 11:24 CET

BioNTech, XPhyto Therapeutics, Valneva - Where are the Corona winners?

  • Biotechnology

Even if the Corona coverage, which has prevailed for 2 years, has recently been replaced by the Ukraine conflict, the pandemic is not yet over. RKI chief Wieler recently reported increased outbreaks in nursing homes and rising incidences among the elderly. Health Minister Lauterbach also sees the wave not yet broken and reports the highest death rates in months. Since the legal basis for the Corona measures expires on March 19, a new law has been introduced to allow measures to be enacted beyond that date. Which companies could benefit?

Read

Commented by Carsten Mainitz on February 24th, 2022 | 11:30 CET

SYNLAB, XPhyto, Novavax - How long will the Corona boom last?

  • Biotechnology

Corona has been turning the world upside down for two years. Although the stock markets have largely recovered from their crash in February and March 2020 and are clearly up again, some stocks are still doing much better, thanks to Corona. For example, shares of companies involved in developing and producing Corona vaccines, medicines, or testing methods have significantly outperformed the indices. But how sustainable is this boom?

Read

Commented by Stefan Feulner on February 14th, 2022 | 12:17 CET

BioNTech, XPhyto, Steinhoff - Explosives for the stock markets

  • Biotechnology

The situation on the stock markets remains tense. Due to the persistently high inflation figures, voices are becoming increasingly louder, calling for far more than the originally planned 3 interest rate hikes by the FED for this year. The ECB should also not be long in finally abandoning its ultra-loose monetary policy. And to make matters worse, the situation in Ukraine is threatening to escalate. The US already reacted to the tense situation and withdrew embassy staff from the Ukrainian capital Kiev.

Read

Commented by André Will-Laudien on February 3rd, 2022 | 13:55 CET

Novavax, XPhyto Therapeutics, BioNTech, Valneva - The vaccine blockbusters are on the move again!

  • Biotechnology

It is on again with the vaccine producers. Experts consider the pandemic to be over by the summer of 2022, but vaccination rates are still low, and infection figures are rushing from record to record. Meanwhile, mandatory vaccination by law is also a daily topic of discussion, dividing society into at least two camps. According to the thinking of those currently taking action, the right to freedom of bodily integrity probably ceases when third parties could suffer a disadvantage as a result of one's own decision. It's so easy to knit laws under the postulate of "protection & general welfare," and the individual right to liberty under the Basic Law is thus unceremoniously nullified. After all, members of parliament are supposed to be able to vote without factional coercion. We evaluate the chances of the well-known biotech protagonists!

Read

Commented by Nico Popp on January 27th, 2022 | 10:13 CET

Valneva, XPhyto, Peloton Interactive: What is next for pandemic stocks?

  • Biotechnology

The pandemic is entering a new phase. Although incidences are rising towards the 1,000 mark, the population is largely relaxing. In the meantime, almost everyone knows someone who has fallen ill; as a rule, the scare is over quickly for those who have been vaccinated. In this article, we look at what this means for the stock market.

Read

Commented by Mario Hose on January 13th, 2022 | 12:01 CET

Stocks offer trading opportunities: BrainChip, TeamViewer, XPhyto

  • Trading

On Thursday, most German indices started trading with negative signs. The DAX is currently trading at 15,989 points, down around 0.25%. The psychological mark of 16,000 points has not held compared to the previous day. The MDAX last traded at 34,874 points (-0.14%), TecDAX at 3,637 points (-0.62%) and SDAX at 16,062 points with 0.13% in the red. In the single stocks, on the other hand, there are exciting developments for the stock traders.

Read

Commented by Armin Schulz on January 12th, 2022 | 13:42 CET

Bayer, XPhyto Therapeutics, MorphoSys - Which pharmaceutical companies bring returns?

  • Biotechnology

Most recently, the pharmaceutical industry has been accused of being greedy and getting rich off Corona. While it is true that 2021 has been dominated by vaccine news, the industry can do much more than just produce vaccines against Corona. Handelsblatt ran a headline on January 10, "In the shadow of Corona," citing the growing number of cancers over the past several years. This year, more than 45 new drugs are expected to hit the market to help fight cancer and genetic defects, among other things. Today, we look at three companies that do not make Corona vaccines.

Read

Commented by Nico Popp on January 7th, 2022 | 12:51 CET

BioNTech, XPhyto, Valneva: 3 stocks for next week?

  • Biotechnology

Omicron is slowly but surely making its presence felt in Germany. After the holidays, when first there is less testing, and secondly the fax machines in German health offices are at a standstill, the official statistics are becoming a little more accurate again. There are already signs of where the journey might be headed. If the past week's growth remains constant, the incidence could already be above the 500 mark in 7 to 10 days. Although such projections are subject to error, it is worth looking at the typical pandemic stocks.

Read